Citations 2
International consensus statement on the use of disease-modifying agents in multiple sclerosis
Freedman, M. S., Blumhardt, L. D., Comi, Giancarlo , Noseworthy, J H, Sandberg‐Wollheim, Magnhild, Brochet, Bruno , Sørensen, Per Soelberg
Multiple Sclerosis Journal | March 4, 2009 | Volume: 8 | Issue: 1_suppl | Pages: 19-23
Objective:To provide recommendations on the use of disease-modifying agents in the management of multiple sclerosis (MS) and to ensure that treatment will be available to those patients who may benefit.Methods:An initial draft of the consensus statement was prepared by the Steering Committee and amended in the light of written comments from a group of MS specialists. At a subsequent workshop, the wording of the consensus statement was discussed, modified if necessary, and the participants indicated their level of support using an electronic voting system. A new draft of the statement was then sent to a much larger group of international opinion leaders in MS for further comment.Results:A number of statements were agreed, which outline the criteria for consideration of disease-modifying therapy for MS and recommendations for treatment. Each statement was accepted completely, or with only minor reservations by 95% or more of those present at the workshop. Conclusions: Periodic reviews and modifications to the statement will be required, as new approaches to the treatment of MS and other therapeutic agents become available. Multiple Sclerosis (2002)8,19-23
International consensus statement on the use of disease-modifying agents in multiple sclerosis
Freedman, M. S., Blumhardt, L. D., Comı, Gıancarlo , Noseworthy, J H, Sandberg‐Wollheim, Magnhild, Sørensen, Per Soelberg , Group, Paris Workshop, Brochet, Bruno , Group, Paris Workshop
Multiple Sclerosis Journal | July 27, 2002 | Volume: 8 | Issue: 1 | Pages: 19-23
Objective: To provide recommendations on the use of disease-modifying agents in the management of multiple sclerosis (MS) and to ensure that treatment will be available to those patients who may benefit. Methods: An initial draft of the consensus statement was prepared by the Steering Committee and amended in the light of written comments from a group of MS specialists. At a subsequent workshop, the wording of the consensus statement was discussed, modified if necessary, and the participants indicated their level of support using an electronic voting system. A new draft of the statement was then sent to a much larger group of international opinion leaders in MS for further comment. Results: A number of statements were agreed, which outline the criteria for consideration of disease-modifying therapy for MS and recommendations for treatment. Each statement was accepted completely, or with only minor reservations by 95% or more of those present at the workshop. Conclusions: Periodic reviews and modifications to the statement will be required, as new approaches to the treatment of MS and other therapeutic agents become available.